Recurrent Gallbladder Carcinoma With pMMR/MSS
收藏NIAID Data Ecosystem2026-03-13 收录
官方服务：
资源简介：
One recurrent GBC patient with pMMR/MSS was treated with camrelizumab plus apatinib. After 4 cycles of combination therapy, the patient achieved a durable complete response with manageable toxicity. The next generation sequencing and immunohistochemistry analysis showed that tumor mutation burden (TMB) was 7.26 Mutants/Mb and PD-L1 expression was 10% (tumor proportion score) and 20% (immune proportion score).
创建时间：
2021-12-05
